Personalis, Inc. (PSNL)

Personalis, Inc. experienced several stock events in the past six months. The stock saw a 7.0% gain on October 30, 2025, and secured Medicare coverage for breast cancer surveillance in November 2025 and for lung cancer surveillance in February 2026. The company reported Q4 2025 revenue of $17.3 million, falling slightly short of estimates, and a net loss of -$23.8 million. The stock price decreased by 24.9% from the start of 2026 to May 9, 2026. Dr. Richard Chen was appointed as President on March 16, 2026, to accelerate MRD adoption. In April 2026, Personalis highlighted the clinical impact of its ctDNA monitoring at the AACR Annual Meeting. The company reported Q1 2026 revenue of $15.5 million, a 25% decrease year-over-year, and a net loss of $30.0 million. Clinical test revenue significantly increased, and the company reaffirmed its full-year 2026 outlook. Following the Q1 earnings announcement, Personalis shares saw a minor increase in aftermarket trading.

Personalis, Inc. experiences demand seasonality for its products and services, with the first quarter typically being the most challenging. Despite this, the company reported strong clinical test volume growth in Q1 2026, reflecting strong market demand for its NeXT Personal test. The company's strategy to "Win-in-MRD" and expand Medicare coverage is aimed at driving consistent demand.

Personalis, Inc. is a healthcare company based in Fremont, California, specializing in advanced genomics for precision oncology. The company focuses on transforming cancer management through personalized testing, offering highly sensitive assays that combine tumor-and-normal profiling with proprietary algorithms to generate genomic insights into cancer's evolution. Its major products and services are designed to detect minimal residual disease (MRD) and cancer recurrence early, enable targeted therapy selection through ultra-comprehensive genomic profiling, and enhance biomarker strategies for drug development. Key product lines and platforms include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and Real-Time Variant Tracker. Personalis generates revenue primarily from sequencing and data analysis services and is the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP).

Personalis, Inc.'s corporate headquarters and clinical laboratory are located in Fremont, California, USA. The company also maintains a European office in West Wickham, Kent, UK, and serves customers across North America, Europe, and the Rest of the World. The company operates one of the largest sequencing laboratories globally.

Personalis, Inc. maintains a strong brand reputation within the precision oncology and genomics fields. Medicare coverage approvals for breast and lung cancer surveillance have positively impacted its reputation. Scientific presentations and publications, including data presented at the AACR Annual Meeting and publications in the Journal of Clinical Oncology and Cell, have further enhanced its reputation. The early access launch of the Real-Time Variant Tracker for NeXT Personal has also contributed positively. Analysts have given Personalis a "Moderate Buy" consensus rating, suggesting significant upside potential.

Personalis, Inc. has a diverse ownership structure. Institutional investors hold a significant stake, with approximately 42% or 34.20% of the company's stock. The general public holds about 17% or 52.57% of the shares. Private equity firms hold approximately 9.2% ownership, and insiders own about 13.23% of the stock. Major institutional owners include Merck & Co., Inc., T. Rowe Price Investment Management, Inc., Lightspeed Management Company, L.L.C., and ARK Investment Management LLC, among others.